肿瘤异质性
精密医学
靶向治疗
癌变
后天抵抗
表型
生物
计算生物学
免疫监视
生物信息学
医学
癌症研究
免疫系统
癌症
免疫学
遗传学
基因
作者
Andriy Marusyk,Michalina Janiszewska,Kornélia Polyák
出处
期刊:Cancer Cell
[Cell Press]
日期:2020-04-01
卷期号:37 (4): 471-484
被引量:735
标识
DOI:10.1016/j.ccell.2020.03.007
摘要
Advances in our understanding of molecular mechanisms of tumorigenesis have translated into knowledge-based therapies directed against specific oncogenic signaling targets. These therapies often induce dramatic responses in susceptible tumors. Unfortunately, most advanced cancers, including those with robust initial responses, eventually acquire resistance to targeted therapies and relapse. Even though immune-based therapies are more likely to achieve complete cures, acquired resistance remains an obstacle to their success as well. Acquired resistance is the direct consequence of pre-existing intratumor heterogeneity and ongoing diversification during therapy, which enables some tumor cells to survive treatment and facilitates the development of new therapy-resistant phenotypes. In this review, we discuss the sources of intratumor heterogeneity and approaches to capture and account for it during clinical decision making. Finally, we outline potential strategies to improve therapeutic outcomes by directly targeting intratumor heterogeneity.
科研通智能强力驱动
Strongly Powered by AbleSci AI